Neogen, Alto Neuroscience, RxSight, and Replimune face class action lawsuits.

Bragar Eagel & Squire has filed class action lawsuits on behalf of stockholders of Neogen Corporation, Alto Neuroscience, RxSight, and Replimune Group. The lawsuits allege violations of the Securities Exchange Act of 1934 due to misrepresentations and omissions regarding the companies' financial health and integration issues. Stockholders have until September 16, 2025, to petition the court to serve as lead plaintiff.

Bragar Eagel & Squire, P.C., a nationally recognized law firm, has filed class action lawsuits on behalf of stockholders of Neogen Corporation, Alto Neuroscience, RxSight, and Replimune Group. The lawsuits allege violations of the Securities Exchange Act of 1934 due to misrepresentations and omissions regarding the companies' financial health and integration issues.

Neogen Corporation (NASDAQ: NEOG)
The lawsuit against Neogen Corporation alleges that the company misrepresented the status of its 3M integration and failed to disclose the negative impact of integration issues on its financial health. The class period for Neogen runs from January 5, 2023, through June 3, 2025, with a deadline for lead plaintiff petitions set for September 16, 2025 [1].

Alto Neuroscience, Inc. (NYSE: ANRO)
The class action lawsuit against Alto Neuroscience, Inc. alleges that the company negligently prepared its IPO offering documents and failed to disclose that its drug ALTO-100 was less effective in treating MDD than previously stated. The class period for Alto runs from February 2, 2024, through October 22, 2024, with a deadline for lead plaintiff petitions set for September 19, 2025 [1].

RxSight, Inc. (NASDAQ: RXST)
The lawsuit against RxSight, Inc. alleges that the company made false and/or misleading statements and failed to disclose adoption challenges and structural issues leading to declines in sales and utilization. The class period for RxSight runs from November 7, 2024, through July 8, 2025, with a deadline for lead plaintiff petitions set for September 22, 2025 [1].

Replimune Group, Inc. (NASDAQ: REPL)
The class action lawsuit against Replimune Group, Inc. alleges that the company failed to disclose the U.S. Food and Drug Administration's (FDA) Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma. The class period for Replimune runs from November 22, 2024, through July 21, 2025, with a deadline for lead plaintiff petitions set for September 22, 2025 [1].

Investors in these companies are encouraged to contact Bragar Eagel & Squire, P.C., to learn more about their legal rights and options for recovering losses. The firm has offices in New York, California, and South Carolina and represents individual and institutional investors in complex litigation.

References:
[1] https://www.globenewswire.com/news-release/2025/08/30/3141865/0/en/Bragar-Eagel-Squire-P-C-Reminds-Investors-of-Class-Actions-Against-Neogen-Alto-RxSight-and-Replimune-and-Encourages-Investors-to-Contact-the-Firm.html